Candriam S.C.A. Takes $8.79 Million Position in MBX Biosciences, Inc. $MBX

Candriam S.C.A. acquired a new position in shares of MBX Biosciences, Inc. (NASDAQ:MBX) in the first quarter, according to its most recent 13F filing with the SEC. The institutional investor acquired 294,374 shares of the company’s stock, valued at approximately $8,787,000.

A number of other institutional investors also recently added to or reduced their stakes in MBX. Hudson Bay Capital Management LP bought a new position in MBX Biosciences in the third quarter worth about $1,488,000. Aaron Wealth Advisors LLC boosted its holdings in shares of MBX Biosciences by 40.0% in the 4th quarter. Aaron Wealth Advisors LLC now owns 70,000 shares of the company’s stock valued at $2,208,000 after buying an additional 20,000 shares in the last quarter. Goelzer Investment Management Inc. purchased a new position in shares of MBX Biosciences in the 4th quarter worth approximately $6,992,000. Baker BROS. Advisors LP acquired a new stake in MBX Biosciences in the third quarter valued at approximately $4,861,000. Finally, Eventide Asset Management LLC acquired a new stake in MBX Biosciences in the fourth quarter valued at approximately $28,071,000.

MBX Biosciences Stock Performance

NASDAQ MBX opened at $61.05 on Monday. The company has a fifty day simple moving average of $40.35 and a two-hundred day simple moving average of $35.91. The stock has a market cap of $2.91 billion, a P/E ratio of -27.62 and a beta of 0.16. MBX Biosciences, Inc. has a 12-month low of $9.63 and a 12-month high of $66.55.

Wall Street Analysts Forecast Growth

Several analysts have recently commented on the company. Stifel Nicolaus set a $56.00 price objective on MBX Biosciences in a report on Tuesday, May 12th. Barclays boosted their target price on MBX Biosciences from $66.00 to $70.00 and gave the stock an “overweight” rating in a research note on Tuesday, May 12th. Truist Financial increased their price target on MBX Biosciences from $50.00 to $70.00 and gave the company a “buy” rating in a research note on Monday, May 11th. Lifesci Capital raised MBX Biosciences to a “strong-buy” rating in a report on Tuesday, March 31st. Finally, Citizens Jmp boosted their price target on MBX Biosciences from $76.00 to $86.00 and gave the stock a “market outperform” rating in a research note on Tuesday, May 12th. One research analyst has rated the stock with a Strong Buy rating, ten have issued a Buy rating and two have assigned a Sell rating to the company. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $60.22.

MBX Biosciences Profile

We are a clinical-stage biopharmaceutical company focused on the discovery and development of novel precision peptide therapies for the treatment of endocrine and metabolic disorders. Our company was founded by global leaders with a transformative approach to peptide drug design and development. Leveraging this expertise, we designed our proprietary Precision Endocrine Peptide™, or PEPTM, platform to overcome the key limitations of unmodified and modified peptide therapies and to improve clinical outcomes and simplify disease management for patients.